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Objective: CD3+CD8+CD28− cells are higher in Rheumatoid Arthritis (RA). The aim of
this study was to assess CD3+CD8+CD28− cells in patients with early RA and assess
the effects of cytomegalovirus (CMV) seropositivity.
Method: In this prospective observation study, 50 RA patients were recruited from
Cardiff University Hospital of Wales (UHW) rheumatology outpatient, 25 patients with
early disease (disease duration 0–6months) and 25 patients with established disease (>2
years). These were compared with 25 healthy controls. Clinical and serological markers
of inflammation were noted, and peripheral blood mononuclear cells were analyzed using
flow cytometry.
Results: The percentage of the CD8+CD28− T cells was increased in RA patients
and was associated with disease duration. The percentage of CD8+CD28− T cells was
increased in CMV positive early and established RA grouped and early RA patients
in comparison to CMV negative patients (p < 0.05). There is a weak but statistically
significant correlation between the percentage of CD3+CD8+CD28− cells and CRP in
CMV positive RA patients (r = 0.227, p < 0.05).
Conclusion: The percentage of CD8+CD28− T cells is higher in RA patients and
correlates with disease duration, highlighting a potential role early in the disease process.
These cells were also higher in CMV positive early RA patients which may suggest a role
of CMV in disease development.
Keywords: CMV, Rheumatoid Arthritis, DAS28, CRP, RF, ACPA, CD28−, T cells
KEY MESSAGES
• CD3+CD8+CD28− cells are increased in RA and correlated with disease
duration.
• CD3+CD8+CD28− cells are higher in CMV positive patients.
• CD3+CD8+CD28− cells are weakly associated with CRP.
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INTRODUCTION
CD8+ T cells are important in controlling viral infection. Acute
viral infection promotes the expansion of CD8+ cells, which
express CD45Ro, CD38 and HLA-DR, CD28, and CD27. CD28
is a key co-stimulatory molecule expressed on naïve CD4+ and
CD8+ T cells. Activation of the T cell receptor with antigen
presenting cells (APCs) via MHC-I-bound peptide antigen has
low affinity and is therefore insufficient to induce full activation
and survival of T cells. The co-stimulatory signal from CD28 cell
surface receptor which interacts with CD86 or CD80 on antigen
presenting cells, is needed to prolong T cell responses (1).
Alongside CD8+ T cells CD4+ T cells also play a key role in
the defense against CMV infection. CMV infection increases the
number of CD4+CD28− T cells (2). CMV specific CD4+ T cells
precede the appearance of CMV specific CD8+ T cells during
primary infection, but are delayed in symptomatic patients (3, 4).
Several studies have reported significant differences between
RA patients and healthy controls with respect to the frequency
of CD4+CD28− T cells (5–7). However, few have accounted
for CMV seropositivity. RA patients have significant expansions
of the CD4+CD28− T cells in CMV positive compared to
CMV negative and this is associated with more severe joint
destruction (8).
Persistent T cell stimulation and proliferation down-regulate
CD28 expression and causes shortening of telomeres in these cells
(9). The loss of CD28 on CD8 cells has also been considered a
marker of immunosenescence and highly differentiated or late
differentiated cells (10). High TNF concentrations, as in the
case with RA, also abrogate CD28 transcription (11). The loss
of CD28 is combined with increased expression of CD57 (12).
The proportion of CD8+CD57+ and CD8+CD28−T cells were
significantly higher in RA patients compared with age-matched
controls (13). However, their exact role in RA in unknown. Some
evidence suggest they may be pro-inflammatory as they express
TNF and IFN-γ (14). We have shown CD8+CD28− T cells from
healthy individuals suppressed autologous mixed lymphocyte
proliferation although this was impaired in patients with RA
(15). This dysfunction was partially reversed by TNF inhibitor
therapy. Furthermore, the immunosuppressive form of IFN-γ
correlates with CD8+CD28− T cells, so might be considered as
CD8+ regulatory T cells (Treg) (15, 16).
Cytomegalovirus (CMV), can shape the human memory T
cell compartment by generating terminally differentiated T cells,
which are characterized by the loss of CD27 and CD28, shortened
telomeres (17), and by the expression of inhibitory natural killer
(NK) cell receptors. CD8+ T cells restrict CMV replication
but do not eliminate or stop transmission. Repeated rounds of
antigen-driven proliferation by CMV continue to cause the clonal
Abbreviations: APC, antigen presenting cells; MHC, major histocompatibility
complex; HLA, human leucocyte antigen; CD, cluster of differentiation; TNF,
tumor necrosis factor; RA, rheumatoid arthritis; Treg, regulatory T cell;
CMV, cytomegalovirus; NK, natural killer cells; UHW, university hospital
of wales; ACR, American college of rheumatology; DAS28, disease activity
score 28; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antigen; ESR,
erythrocyte sedimentation ratio; CRP, C reactive protein; PBMCs, peripheral blood
mononuclear cells.
expansion of CMV-specific CD8+ T cells, which accumulate with
age. Chronic CMV infection expands a population of CD8+ T
cells that can efficiently control latent infection, while certain
effector function are reduced to prevent harm due to collateral
autoreactivity (18). Latent CMV infection and RA share several
phenotypical features in the T cell compartment. CD8+CD28−
T cells are expanded in healthy individuals chronically infected
with CMV, and even more so in CMV infected RA patients
(19). CMV positivity has been associated with more severe joint
destruction in RA (8) and CMV IgG positivity is lower in
controlled RA compared to active RA (20).
The aim of this paper is to establish whether CD8+CD28−
T cells are raised in Early as well as Established RA, and
furthermore to examine the effect of prior CMV exposure on this
subtype of cells.
METHOD
Patients
The study was approved by the South East Wales Research Ethics
Committee, Panel B in 2011 (REC reference: 11/WA/0326).
Cardiff University was responsible for the governance of the
study with reference number 11/CMC/5299. The Cardiff and
Vale University Health Board Research & Development Office
approved the proposal in 2013.
In this prospective observation study, 50 RA patients (25
early and 25 established disease) were recruited from University
Hospital of Wales (UHW) rheumatology outpatient clinic
in Cardiff. Twenty-five healthy controls were recruited from
Cardiff University.
Inclusion criteria included the following: age ≥18 years;
ACR/EULAR 2010 criteria of RA diagnosis (21); duration of
persistent symptoms in the Early RA group of 4 weeks to 6
months or>2 years since diagnosis for the established RA group.
Exclusion criteria include the following: other
autoimmune/inflammatory rheumatic disease; heart disease
classified as New York Heart Foundation Functional class
IV (ACR classification); treatment with intravenous gamma
globulin, plasmapheresis, or ProsorbaTM column within the last
6 months.
Clinical Assessments
Clinical assessments included age, gender, RA disease duration,
Disease Activity Score 28 (DAS28) score and blood was
taken to asses Rheumatoid Factor (RF), Anti-citrullinated
Peptide Antigen (ACPA), Erythrocyte Sedimentation Rate (ESR),
C-Reactive Protein (CRP), and CMV status (IgG positive
or negative).
Immunofluorescence and Flow Cytometry
Peripheral blood mononuclear cells (PBMCs) were collected
from subjects into two 4ml BD VacutainersTM then centrifuged
and purified. T cell staining with fluorescently conjugated
antibodies using anti-CD3 (APC-Cy7, BD Biosciences), anti-
CD8 (Pe-Vio-770, Miltenyi Biotec Ltd.), anti-CD28 (eFluor 450,
eBioscience) were prepared for flow cytometric analysis of cells.
Cells were acquired using a CyAn ADP (Beckman Coulter) flow
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TABLE 1 | Demographics of health controls, early, and established RA patients recruited (A) and demographics of the patients tested for CMV positivity at baseline (B).
(A)
Healthy controls (n = 25) Early RA (n = 25) Established RA (n = 25)
Age 41 ± 12 56 ± 12 62 ± 12
Disease duration N/A 4 ± 1.2 months 10 ± 7.6 years
RF positive (%) N/A 17 (68) 14 (56)
ACPA positive (%) N/A 19 (79) 15 (63)
DAS28 N/A 4.07 ± 1.3 5.4 ± 1.9
Female (%) 17 (68) 16 (64) 17 (68)
(B)
Early RA Established RA Pooled RA
CMV negative CMV positive CMV negative CMV positive CMV negative CMV positive
Number of patients 12 13 7 5 19 18
Duration disease 3.7 ± 1.2 months 4.1 ± 1.5 months 8.1 ± 9.0 years 11.8 ± 5.9 years N/A N/A
Age 52 ± 15 61 ± 8 65 ± 10 66 ± 11 56 ± 14 56 ± 9
RF positive (%) 9 (75) 7 (54) 3 (43) 4 (80) 12 (63) 11 (61)
ACPA positive (%) 10 (83) 9 (69) 3 (43) 3 (75) 13 (68) 12 (67)
Mean DAS28 4.0 ± 1.1 4.2 ± 1.6 5.3 ± 1.0 4.8 ± 2.3 4.4 ± 1.2 4.3 ± 1.8
Female % 58 (7) 77 (10) 71 (5) 80 (4) 68 (13) 78 (14)
Percentages are shown with number of subjects in brackets. Mean average is presented. Age and DAS28 are shown with standard deviation.
cytometer and analyzed using Summit software (software version
4.3; Beckman Coulter).
Statistics
Statistical analysis was performed using GraphPad Prism v5
software. Pairwise comparisons were determined using the
Mann Whitney U-Test. Comparison of multiple groups was
assessed using ANOVA with Holm-Sidak correction for multiple
comparison. For non-parametric data, Kruskal-Wallis and
post-hoc Dunn’s tests were used. P < 0.05 was considered
significant. The Spearman rank correlation was used to analyse
statistical associations.
RESULTS
Demographic data and clinical characteristics are shown in
Table 1. There were 25 patients with Early RA, 25 patients with
Established RA and 25 healthy controls. The mean age of the
patient groups was similar (56 in Early RA and 62 in Est RA).
The mean age of the healthy controls was 41. Disease activity was
higher in the Est RA group (DAS28: 5.4 and 4.07, respectively).
The proportion of female subjects in each group was similar
(between 64 and 68%). Twenty-five Early RA patients were
tested for CMV (52% positive), 12 of the Est RA were tested
(42% positive).
CD8+CD28− T Cells in Early and
Established RA
Percentage of CD8+CD28− T cells in Early and Established
RA was statistically significantly higher (%) than Controls
(p= 0.048, Figure 1B).
In early RA patients, percentage of CD8+CD28− T cells
correlated with disease duration (r = 0.491, p = 0.013,
Figure 1C). Percentage of CD8+CD28− T cells was increased in
CMV positive early RA patients in comparison to CMV negative
early RA patients (Figure 1D). In contrast, the percentage of
CD8+CD28− T cells did not correlate with disease duration in
established RA (r = 0.164, p= 0.433) data not shown. There was
no correlation with measurement of disease activity by disease
activity score 28 (DAS28), which includes a tender and swollen
joint count, ESR or CRP and pain score (early RA: r = 0.003, p=
0.812, established RA: r = 0.020, p= 0.524).
For RF negative patients, the percentage of CD8+CD28− T
cells was higher in CMV positive grouped early and established
RA patients, than CMV negative (p < 0.05, Figure 1E). The
association between RF and CD4+CD28− T cells in RA
and control patients has previously been investigated, and
no statistical difference was observed (p = 0.062) in our
study (22). Similarly, CD8+CD28− T cells percentage was not
associated with ACPA seropositivity (data not shown). Both RF
and ACPA are autoantibodies that signify a poorer prognosis
in RA.
There is a weak but statistically significant correlation
between the percentage of CD8+CD28− T cells and CRP
in CMV positive early and established RA patients (r =
0.227, p = 0.045, Figure 1F). There was no correlation
between CD3+CD8+CD28− T cells and ESR (CMV
positive early and established RA patients: r = 0.439,
p = 0.069) data not shown. CRP has not previously
been found to be associated with CD8+CD28− or
CD4+CD28− T cell accumulation in the context of CMV
seropositivity (23).
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FIGURE 1 | The percentage of CD3+CD8+CD28− T Cells is higher in early and established RA grouped (B). Flow cytometry gating strategy for lymphocytes, single
cells and CD3+CD8+ and CD3+CD8+CD28− (A). There is low level correlation between the percentage of CD3+CD8+CD28− T cells and Disease Duration in Early
(Continued)
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FIGURE 1 | RA patients (C). Peripheral blood CD3+CD8+CD28− T cells are also increased in CMV positive early RA patients (C, n = 25, CMV positive = 13, CMV
negative = 12). When RA patients are Rheumatoid Factor (RF) negative, the percentage of CD3+CD8+CD28− cells is higher in CMV positive patients (E, n = 37).
There is a weak statistically significant correlation between the percentage of CD3+CD8+CD28− cells and C reactive protein (CRP) in CMV positive early and
established RA grouped patients (F). Percentage of CD3+CD8+CD28− T Cells are shown with median, *p < 0.05 by Mann-Whitney U-Test (B,D) or One-way ANOVA
Test with Holm-Sidak analysis for multiple comparisons (E). Controls (n = 24), early and established RA grouped (n = 50), Early RA (n = 25), Established RA (n = 25).
Correlation was determined using non-parametric Spearman’s rank analysis, *p < 0.05. Early and established grouped RA (E,F, n = 37), Early RA (n = 25), Est RA (n
= 12), CMV positive (n = 18).
DISCUSSION
CD8+CD28− T cells have been shown to be raised in RA. In this
study, we found that increase in CD8+CD28− T cells occurred
early and correlate with disease duration suggesting they have
a possible role early in the disease process. The expansion of
this cell subset could be contributing to immune disturbance in
RA. Alternatively, these cells could reflect a bystander population
that reflects an active autoimmune process in early disease.
The number of studies on the role of CD8+ T cells in the
pathogenesis of RA is scant However, increased frequency of
CD8+ T cells are found in the lymph node and peripheral blood
of patients with RA suggest they may be important in early
disease development (24).
Similar to the previous study by Ceeraz et al. (15), we also
found no significant correlation with the disease activity score
and CD8+CD28− T cells in established RA (6). However, in this
study, we found statistically significant correlation between CRP
and CD8+CD28− T cells in early RA suggesting their function
may change during chronic disease.
CMV status was associated with the percentage of the
CD8+CD28− T cells which was increased in CMV positive
early RA patients in comparison to CMV negative early RA
patients. CD8+CD28− T cells have been found to be significantly
increased in CMV positive compared to CMV negative in
other autoimmune diseases (25). Our findings that percentage
of the CD8+CD28− T cells was increased in CMV positive
early RA patients in comparison to CMV negative early RA
patients was in keeping with this. Although in RA patients the
number of EBV-specific CD8+ T-cells correlates positively with
the viral load, the CD8+ T-cell responses to CMV antigens do
not (26).
Increased in CD8+CD28− cells could be due to prior
CMV infection because CMV infection is known to
increase the absolute number of CD8+CD28−lymphocytes
(27). Indeed, this was the case in this study. Latent
CMV infection may prime memory T cells response so
that when RA develops, this may lead to more severe
disease (10).
A limitation of this study was that the number of Established
RA patients that were tested for CMV was low (12/25).
Therefore, subdivision into Established RA would not have
sufficient statistical power for sub-analysis into this group.
Increasing the sample size, particularly the Established RA group,
would increase the power of the study and allow for further
sub-group analysis.
In conclusion, the percentage of CD8+CD28− T cells is
higher in early RA and further increased in CMV positive early
RA patients. In RF negative RA patients, the percentage of
CD8+CD28− T cells is higher in CMV positive patients and there
is weak positive correlation of CD8+CD28− T cells with CRP.
CONCLUSIONS
The percentage of CD8+CD28− T cells is higher in RA patients
and correlates with disease duration in early RA patients,
highlighting a potential role early in the disease process. These
cells were also higher in CMV positive early RA patients which
may suggest a role of CMV in disease development.
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